Ligand Pharmaceuticals

LGND · NASDAQ

$306.40+$9.12 (+3.07%)TodayMarket closed · Oct 20, 7:59 PM ET

Prev close $297.28

Latest news

Press releaseOct 15, 7:00 AM ETGlobe Newswire
Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026
NewsOct 7, 4:00 AM ET
Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call
Press releaseSep 24, 7:00 AM ETGlobe Newswire
Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million
Press releaseSep 22, 9:02 AM ETBusiness Wire
Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®
Press releaseSep 22, 9:00 AM ETPRNewswire
Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners
Press releaseSep 22, 7:00 AM ETGlobe Newswire
Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million
Press releaseAug 10, 4:12 PM ETGlobe Newswire
Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates
Press releaseAug 6, 7:00 AM ETGlobe Newswire
Ligand Reports Second Quarter 2026 Financial Results
Press releaseJul 23, 7:00 AM ETGlobe Newswire
Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026
NewsJul 14, 11:37 AM ETKaustubh Bagalkote
Why Is Agenus Stock Falling on Tuesday?
Press releaseJul 14, 9:00 AM ETGlobe Newswire
Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets
NewsJul 13, 11:29 AM ETVandana Singh
Why Is Agenus Stock Gaining Monday?
NewsJun 17, 1:35 PM ET
7 Health Care Stocks With Whale Alerts In Today's Session
Press releaseMay 12, 4:18 PM ETGlobe Newswire
Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates
NewsMay 7, 7:04 AM ET
Ligand Pharmaceuticals Q1 Adj. EPS $1.63 Misses $1.82 Estimate, Sales $51.722M Miss $58.696M Estimate
Press releaseMay 7, 7:00 AM ETGlobe Newswire
Ligand Reports First Quarter 2026 Financial Results
Press releaseMay 6, 8:01 AM ETGlobe Newswire
Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement
Press releaseApr 28, 12:45 PM ETBusiness Wire
XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA
Press releaseApr 27, 3:06 PM ETPRNewswire
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation
NewsApr 27, 1:18 PM ETVandana Singh
Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million
NewsApr 27, 7:06 AM ET
Ligand Pharmaceuticals To Acquire XOMA Royalty For $39.00 Per Share In Cash, Ligand Raises FY2026 Adj. EPS Guidance To $8.50-9.50 And Expects The Transaction To Be Accretive By $1.50 Per Share To Adj. EPS In 2027
Press releaseApr 27, 7:00 AM ETGlobe Newswire
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator
Press releaseApr 22, 7:00 AM ETGlobe Newswire
Ligand to Report First Quarter 2026 Financial Results on May 7, 2026
NewsMar 11, 2:11 PM ETVandana Singh
Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst
Press releaseFeb 26, 7:00 AM ETGlobe Newswire
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results
Press releaseFeb 12, 7:00 AM ETGlobe Newswire
Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Press releaseDec 9, 7:00 AM ETGlobe Newswire
Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance
NewsNov 7, 7:52 AM ETVandana Singh
EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch
NewsNov 6, 6:12 AM ET
Earnings Scheduled For November 6, 2025
NewsNov 5, 12:02 PM ET
What's Next: Ligand Pharmaceuticals's Earnings Preview
Press releaseOct 23, 7:00 AM ETGlobe Newswire
Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025
Press releaseOct 9, 7:00 AM ETGlobe Newswire
Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients
Press releaseJul 24, 7:00 AM ETGlobe Newswire
Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025
NewsJul 9, 11:06 AM ETAvi Kapoor
Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday
NewsMay 8, 4:33 AM ET
Earnings Scheduled For May 8, 2025
Press releaseApr 24, 7:00 AM ETGlobe Newswire
Ligand to Report First Quarter 2025 Financial Results on May 8, 2025
NewsApr 17, 12:09 PM ETAvi Kapoor
Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings
NewsApr 17, 9:58 AM ETAvi Kapoor
Dow Falls Over 1%; US Initial Jobless Claims Decline
Press releaseMar 31, 7:30 AM ETGlobe Newswire
Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update
Press releaseFeb 27, 7:00 AM ETGlobe Newswire
Ligand Reports Fourth Quarter and Full Year 2024 Financial Results
Press releaseFeb 25, 7:00 AM ETGlobe Newswire
Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences
Press releaseFeb 13, 7:00 AM ETBusiness Wire
Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025
Press releaseFeb 6, 7:00 AM ETBusiness Wire
Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.

Latest news

Ligand to Report Third Quarter 2026 Financial Results on October 29, 2026

Full Transcript: Ligand Pharmaceuticals Q2 2026 Earnings Call

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

Sydnexis Announces Royalty Agreement with Ligand for Ryjunea®

Primrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare Partners

Ligand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 Million

Orchestra BioMed Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Ligand Reports Second Quarter 2026 Financial Results

Ligand to Report Second Quarter 2026 Financial Results on August 6, 2026

Why Is Agenus Stock Falling on Tuesday?

Ligand Completes Acquisition of XOMA Royalty, Creating a Portfolio of More than 200 Biopharmaceutical Royalty Assets

Why Is Agenus Stock Gaining Monday?

7 Health Care Stocks With Whale Alerts In Today's Session

Orchestra BioMed Reports First Quarter 2026 Financial Results and Highlights Recent Business Updates

Ligand Pharmaceuticals Q1 Adj. EPS $1.63 Misses $1.82 Estimate, Sales $51.722M Miss $58.696M Estimate

Ligand Reports First Quarter 2026 Financial Results

Orchestra BioMed Receives $15 Million Investment from Ligand Under Previously Announced Strategic Financing Agreement

XOMA Royalty Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of XOMA Royalty Corporation - XOMA

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of XOMA Royalty Corporation

Ligand Bets On Royalty Growth With XOMA Buyout Worth Over $700 Million

Ligand Pharmaceuticals To Acquire XOMA Royalty For $39.00 Per Share In Cash, Ligand Raises FY2026 Adj. EPS Guidance To $8.50-9.50 And Expects The Transaction To Be Accretive By $1.50 Per Share To Adj. EPS In 2027

Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand's Position as a Leading Biopharma Royalty Aggregator

Ligand to Report First Quarter 2026 Financial Results on May 7, 2026

Ligand Pharmaceuticals Is A Low-Risk Way To Bet On Biopharma Growth: Analyst

Ligand Reports Fourth Quarter and Full Year 2025 Financial Results

Ligand to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

Ligand Hosts 2025 Investor Day and Introduces 2026 Guidance

EXCLUSIVE: Pelthos Secures Rights To Antimicrobial Drug, Raises $18 Million To Support Commercial Launch

Earnings Scheduled For November 6, 2025

What's Next: Ligand Pharmaceuticals's Earnings Preview

Ligand to Report Third Quarter 2025 Financial Results on November 6, 2025

Ligand Partner SQ Innovation Receives FDA Approval for Lasix® ONYU, an At-Home Treatment for Edema in Heart Failure Patients

Ligand to Report Second Quarter 2025 Financial Results on August 7, 2025

Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday

Earnings Scheduled For May 8, 2025

Ligand to Report First Quarter 2025 Financial Results on May 8, 2025

Gold Falls Over 1%; D.R. Horton Posts Downbeat Earnings

Dow Falls Over 1%; US Initial Jobless Claims Decline

Palvella Therapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update

Ligand Reports Fourth Quarter and Full Year 2024 Financial Results

Ligand Leads $75 Million Royalty Financing in Castle Creek Biosciences

Ligand to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

Ligand to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference